Susanne Felgner1, Patricia Ex2, Cornelia Henschke2. 1. Department of Health Care Management, Technische Universität Berlin, Berlin, Germany. Electronic address: susanne.felgner@tu-berlin.de. 2. Department of Health Care Management, Technische Universität Berlin, Berlin, Germany.
Abstract
OBJECTIVES: To foster value-based pricing and coverage with evidence development in Germany, certain new diagnostic and treatment methods have been subject to a benefit assessment since 2016 to determine their reimbursement. Although this is a paradigm shift, the German approach is limited to some few specific technologies for which reimbursement is requested. As physicians encounter this regulatory instrument, the aim of the study was to understand physicians' decision making regarding the adoption of new medical technologies and to identify their perspectives on the evidence base and financing with additional reimbursement systems. METHODS: From April to August 2017, semistructured interviews with chief and senior physicians of vascular surgery and cardiology in inpatient care in Germany were conducted (N = 23). The interviews were carried out by one researcher in one-to-one appointments or via telephone. Data were analyzed inductively to identify factors and generate thematic categories using qualitative content analysis. RESULTS: We identified 52 factors in eight categories influencing physicians' adoption of new technologies. The evidence base for new technologies was criticized (e.g., lack of available studies). Physicians' knowledge of the regulation of market approval and innovation payments varied. They recommended the utilization of new technologies in certain specialist centers and the facilitation of observational studies. CONCLUSIONS: Physicians saw the need for the new approach and supported its aim. However, its design and implementation appeared to be questionable from their medical perspective. The provision of summarized information on the benefit of technologies might be a possibility to assist physicians' decision making.
OBJECTIVES: To foster value-based pricing and coverage with evidence development in Germany, certain new diagnostic and treatment methods have been subject to a benefit assessment since 2016 to determine their reimbursement. Although this is a paradigm shift, the German approach is limited to some few specific technologies for which reimbursement is requested. As physicians encounter this regulatory instrument, the aim of the study was to understand physicians' decision making regarding the adoption of new medical technologies and to identify their perspectives on the evidence base and financing with additional reimbursement systems. METHODS: From April to August 2017, semistructured interviews with chief and senior physicians of vascular surgery and cardiology in inpatient care in Germany were conducted (N = 23). The interviews were carried out by one researcher in one-to-one appointments or via telephone. Data were analyzed inductively to identify factors and generate thematic categories using qualitative content analysis. RESULTS: We identified 52 factors in eight categories influencing physicians' adoption of new technologies. The evidence base for new technologies was criticized (e.g., lack of available studies). Physicians' knowledge of the regulation of market approval and innovation payments varied. They recommended the utilization of new technologies in certain specialist centers and the facilitation of observational studies. CONCLUSIONS: Physicians saw the need for the new approach and supported its aim. However, its design and implementation appeared to be questionable from their medical perspective. The provision of summarized information on the benefit of technologies might be a possibility to assist physicians' decision making.
Authors: Sacha P Broccard; Ali Abbaszadeh Kasbi; Sanjay P Bagaria; Jeremy Jones; Mira Shoudry; Emmanuel M Gabriel Journal: J Gastrointest Oncol Date: 2022-02
Authors: Minh-Phuong Huynh-Le; Randall C Shults; Michael J Connor; Jona A Hattangadi-Gluth Journal: Clin Genitourin Cancer Date: 2019-12-05 Impact factor: 2.872
Authors: Suepattra G May; Caroline Huber; Meaghan Roach; Jason Shafrin; Wade Aubry; Darius Lakdawalla; John M Kane; Felicia Forma Journal: J Med Internet Res Date: 2021-02-03 Impact factor: 5.428
Authors: Patrick Kierkegaard; Timothy Hicks; A Joy Allen; Yaling Yang; Gail Hayward; Margaret Glogowska; Brian D Nicholson; Peter Buckle Journal: Implement Sci Commun Date: 2021-12-18